Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Monte Rosa Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Monte Rosa Therapeutics, Inc.

GLUE

Monte Rosa Therapeutics, Inc.

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics is a biotech company specializing in targeted protein degradation using proprietary molecular glue degraders (MGDs). Its platform employs AI-driven discovery engines to develop small molecules that selectively eliminate disease-causing proteins, including those previously deemed undruggable. Focus areas include oncology, immunology, and inflammation, with a pipeline of clinical and preclinical candidates targeting cancers, autoimmune, and inflammatory diseases. The company leverages collaborations with major pharma to accelerate development.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Monte Rosa Therapeutics, Inc.

1
1
Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics Reports Decrease in Revenue and Increased Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics Reports $123.7M Revenue and Clinical Updates in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics Reports Q3 2025 Financial Results with Increased Collaboration Revenue

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics Reports $23.2M Collaboration Revenue and $12.3M Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics Reports $84.9M Collaboration Revenue and $46.9M Net Income in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics Reports $72.7 Million Net Loss for 2024, Highlights Collaboration Revenue Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics Reports Increased Collaboration Revenue and Reduced Losses, Enters Strategic Partnerships

Via official filing (AI summary) | over 1 year ago | 0 comments